,,ii #aadth ,,congress #ast ,session ,s4 #aeig ,,in ,,the ,,senate ,,of ,,the ,,united ,,states ,june #ag1 #bjae ,mr4 ,wicker 7for himself1 ,ms4 ,klobuchar1 ,ms4 ,collins1 ,mr4 ,franken1 ,mr4 ,isakson1 and ,mr4 ,bennet7 introduced the following bill2 which was read twice and referred to the ,committee on ,health1 ,education1 ,labor1 and ,pensions ,a ,,bill ,to enhance patient engagement in the medical product development process1 and for other purposes4 #a4 ,short title ,this ,act may be cited as the ,patient-,focused ,impact ,assessment ,act of #bjae4 #b4 ,public disclosure of safety and effectiveness data in action package ,paragraph 7#b7 of section #eje7l7 of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cee7l77 is amended-- 7#a7 in subparagraph 7,c71 by adding at the end the following3 7vii7 ,documentation of the patient engagement assessment efforts made as part of the review1 including identification of the patient-focused drug development tools and data reviewed in informing the decision to approve the application1 and including an explanation of whether the following were reviewed or examined3 7,i7 ,patient population benefit and risk data4 7,,ii7 ,draft or final guidances issued by the ,food and ,drug ,administration4 7,,iii7 ,patient-reported or caregiver-reported outcomes data4 7,,iv7 ,patient preference data4 7,v7 ,perspectives of patients serving on advisory committees or participating in medical product development proceedings4 7,,vi7 ,perspectives of medical and scientific professionals with relevant expertise4 7,,vii7 ,other measures to assess the impact of patient-focused drug development tools1 as determined by the ,secretary4 2 and 7#b7 by adding at the end the following3 7,f7 ,annual reports ,the ,secretary shall prepare and submit to the ,committee on ,health1 ,education1 ,labor1 and ,pensions of the ,senate and the ,committee on ,energy and ,commerce of the ,house of ,representatives an annual report summarizing the data collected from the action packages under subparagraph 7,c77vii74 ,such report shall include an assessment by the ,food and ,drug ,administration of the trends of such agency with respect to the use of patient-focused drug development tools in reviewing applications under subsection 7b7 and section #cea of the ,public ,health ,service ,act4 4 #c4 ,guidance to patients and industry on patient-focused drug development 7a7 ,publication of guidance2 contents ,the ,secretary of ,health and ,human ,services 7referred to in this section as the ,secretary71 acting through the ,commissioner of ,food and ,drugs1 shall publish guidance that-- 7#a7 specifies how the ,food and ,drug ,administration views collaboration between patients or patient advocacy organizations and industry sponsors for the purposes of-- 7,a7 developing patient-focused drug development tools2 and 7,b7 obtaining patient perspectives on medical products under development2 7#b7 specifies the position of the ,food and ,drug ,administration with respect to advocacy and industry collaborations that would be permitted to develop such tools and obtain such perspectives2 and 7#c7 specifies the position of the ,food and ,drug ,administration with respect to activities that would not be permitted for such purposes4 7b7 ,timing ,the ,secretary shall-- 7#a7 not later than #f months after the date of enactment of this ,act1 publish proposed guidance under this section2 and 7#b7 not later than #f months after the date of publication of such proposed guidance1 and after providing an opportunity for the public to comment on such proposed guidance1 publish final guidance under this section4